MedPath

JONG HOON LEE

๐Ÿ‡ฆ๐Ÿ‡บAustralia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:0

Trial Phases

2 Phases

Phase 2:1
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)โ€ข Click on a phase to view related trials

Phase 3
2 (66.7%)
Phase 2
1 (33.3%)

Two-week Course Versus Conventionally Fractionated Chemoradiotherapy in Rectal Cancer

Phase 3
Conditions
Response to Toxin
Toxicity
Recurrence
Interventions
Drug: Two-week course of radiation
First Posted Date
2015-06-29
Last Posted Date
2017-06-05
Lead Sponsor
Jong Hoon Lee
Target Recruit Count
370
Registration Number
NCT02484040
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

Lee Jong Hoon, Suwon, Korea, Republic of

3DCRT vs. IMRT in Early Breast Cancer

Phase 3
Conditions
Radiation Toxicity
First Posted Date
2015-05-12
Last Posted Date
2017-06-05
Lead Sponsor
Jong Hoon Lee
Target Recruit Count
690
Registration Number
NCT02440191
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

St. Vincent Hospital, Suwon, Korea, Republic of

Short-course Preoperative Chemoradiotherapy for Rectal Cancer

Phase 2
Conditions
Rectal Cancer
First Posted Date
2011-09-09
Last Posted Date
2017-10-10
Lead Sponsor
Jong Hoon Lee
Target Recruit Count
80
Registration Number
NCT01431599
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

National Cancer Center, Korea, Goyang, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Samsung Medical Center, Seoul, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Seoul National University Hospital, Seoul, Korea, Republic of

News

No news found
ยฉ Copyright 2025. All Rights Reserved by MedPath